Abstracts tagged "skin"

Abstract Number: 1172 • ACR Convergence 2020
Cardiovascular involvement as a clue for diagnosis of Juvenile Systemic Sclerosis sine scleroderma
Gloria Lanzoni¹, Giorgia Martini¹, Alessandra Meneghel¹, Fabio Vittadello², Biagio Castaldi¹, Elisabetta Zanatta³ and Francesco Zulian¹, ¹Department of Woman's and Child's Health, University of Padova, Padua, Italy, ²Centro Studi Statistici Explora, Padua, Italy, ³Department of Medicine-DIMED, University of Padova, Padua, Italy
Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare condition in childhood and its variety with no skin involvement, systemic sclerosis sine scleroderma (JSSSS) is anecdotal…
Abstract Number: 1373 • ACR Convergence 2020
IL-23 Skin and Joint Profiling in Psoriatic Arthritis: Novel Perspectives in Understanding Clinical Responses to IL-23 Inhibitors
Alessandra Nerviani¹, Marie-Astrid Boutet¹, Wang Sin Gina Tan¹, Katriona Goldmann¹, Nirupam Purkayastha¹, Tamas Lajtos¹, Rebecca Hands¹, Myles Lewis¹, Stephen Kelly² and Costantino Pitzalis³, ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Mile End Hospital, Barts Health NHS Trust, London, United Kingdom, ³Queen Mary University of London, London, United Kingdom
Background/Purpose: PsA is a chronic heterogeneous inflammatory condition affecting up to 30% of patients with skin and/or nail psoriasis and the IL-23/IL-17 axis is believed…
Abstract Number: 1397 • ACR Convergence 2020
Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort
Smriti Prasad¹, Samantha Black², Shivani Sharma³ and Heidi Jacobe¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²The University of Texas Southwestern Medical Center, Dallas, TX, ³University of Texas Southwestern, Dallas, TX
Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…
Abstract Number: 1610 • ACR Convergence 2020
Cutaneous Side Effects of Hydroxychloroquine in Rheumatic Diseases –Combination of “Traditional” Multivariate Analysis for Risk Factors AndClassification Model Development Using Supervised Machine Learning –Single Centre Retrospective Cohort Study in India
Sandeep Surendran¹, Mithun CB¹, Arun Tiwari², Vishal Marwaha¹ and Sekhar Easwar¹, ¹Amrita Institute of Medical Sciences, Kochi, Kerala, India., Kochi, Kerala, India, ²Amrita Institute of Medical Sciences, Kochi, Kerala, India., Kochi, India
Background/Purpose: Hydroxychloroquine (HCQ) is associated with varied cutaneous side effects but only few studies in literature characterizing the risk factors for this. Recently machine learning…
Abstract Number: 0076 • ACR Convergence 2020
The Role of Interferon Kappa in Psoriasis
Mehrnaz Gharaee-Kermani¹, Shannon Estadt², Sonya Wolf-Fortune¹, Jianhua Liu¹, Tamra Reed³, Johann Gudjonsson⁴ and J. Michelle Kahlenberg⁵, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ypsilanti, MI, ³University of Michigan, Ann Arbor, ⁴University of Michigan, Ann ArborUniversity of Michigan, ⁵Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Psoriasis is a common, chronic inflammatory autoimmune skin diseases characterized by hyperproliferation and abnormal differentiation of keratinocytes and infiltration of inflammatory cells. Early infiltration…
Abstract Number: 1631 • ACR Convergence 2020
No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program
Mark Lebwohl¹, Darren West², Alan Mendelsohn³, Stephen Rozzo³ and Giampiero Girolomoni⁴, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Spectrum Dermatology, Scottsdale, AZ, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁴Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Tildrakizumab (TIL) is a high‐affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate to severe plaque psoriasis. We evaluated adverse…
Abstract Number: 0263 • ACR Convergence 2020
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
Stephanie Florez-Pollack¹, Syed Rizvi², Benjamin Chong² and Linda Hynan², ¹University of Pennsylvania, PHILADELPHIA, PA, ²University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little…
Abstract Number: 1802 • ACR Convergence 2020
Vitamin D Level: Predictor of SLE Disease Activity in AA Cohort with CLE?
Ileannette Robledo-Vega¹, John Scheinuk², Emmanuel Pardo², Ansley Pratt², Soham Mahato³, Andrew G. Chapple² and Myriam Guevara⁴, ¹Louisiana State University Health Sciences Center, New Orlenas, LA, ²Louisiana State University, New Orleans, LA, ³LSUHSC School of Public Health, New Orleans, LA, ⁴Lousiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: There are few predominant African American (AA) epidemiological studies in Cutaneous Lupus Erythematosus (CLE). The Gilliam classification divides CLE into lupus specific, acute cutaneous…
Abstract Number: 0283 • ACR Convergence 2020
Genome-wide DNA Methylation Analysis in Lupus Keratinocytes Identifies Differential Methylation of Genes That Regulate Apoptosis
Grace Hile¹, Patrick Coit¹, Chang Zeng¹, Rachael Wasikowski², Alex Tsoi², Allison Billi², Johann Gudjonsson³, Amr Sawalha⁴ and J. Michelle Kahlenberg⁵, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann ARbor, ³University of Michigan, Ann ArborUniversity of Michigan, ⁴University of Pittsburgh, Pittsburgh, ⁵Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematous (CLE) is a disfiguring manifestation of systemic LE (SLE), and the pathogenesis remains unclear. However, epidermal regulation of skin inflammation and…
Abstract Number: 1906 • ACR Convergence 2020
Hsp90 Inhibition Effectively Prevents Progression of Dermal Fibrosis and Induces Regression of Established Bleomycin-Induced Dermal Fibrosis
Hana Storkanova¹, Lenka Storkanova², Sabina Oreska³, Maja Spiritovic⁴, Barbora Hermankova⁵, Radim Becvar¹, Karel Pavelka⁶, Jiří Vencovský⁶, Jörg HW Distler⁷, Ladislav Šenolt⁶ and Michal Tomcik¹, ¹Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, ⁴Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic,, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Our previous study demonstrated that Heat shock protein 90 (Hsp90) is overexpressed in the skin of patients with systemic sclerosis (SSc), in cultured SSc…
Abstract Number: 0284 • ACR Convergence 2020
Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-induced Lupus Model
Gantsetseg Tumurkhuu¹, Shuang Chen², Erica Montano¹, Malcolm Lane², Michifumi Yamashita², Janet Markman², Luz Blanco³, Mariana Kaplan⁴, Kenichi Shimada², Timothy Crother², Mariko Ishimori², Daniel J Wallace¹, Caroline Jefferies⁵ and Moshe Arditi², ¹Cedars-Sinai Medical Center, Los Angeles, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁵Cedars-Sinai Medical Center, West Hollywood, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease in which type I interferons (IFN) play a key role. The IFN response can…
Abstract Number: 2033 • ACR Convergence 2020
Large-scale Examination of Longitudinal Skin Gene Expression and Its Associations with Skin Thickness in Systemic Sclerosis
Brian Skaug¹, Marka Lyons¹, William Swindell², Gloria Salazar¹, Julio Charles¹, Connor Vershel¹, Maureen Mayes³ and Shervin Assassi³, ¹University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²The Jewish Hospital, Department of Internal Medicine, Cincinnati, OH, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Numerous studies have revealed dysregulated gene expression in the skin of systemic sclerosis (SSc) patients, with varying degrees of inflammatory/immune and fibroblast upregulation. However,…
Abstract Number: 0318 • ACR Convergence 2020
Oxylipin Profile Is Associated with Skin Disease and Enthesitis in Psoriatic Disease
Roxana Coras¹, Arthur Kavanaugh², Angela Kluzniak³, Dustina Holt³, Amy Weilgosz³, Oswald Quehenberger¹, Christopher Ritchlin⁴ and Monica Guma⁵, ¹University of California San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ³University of Rochester Medical Center, New York, NY, ⁴Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁵Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA), a systemic inflammatory disease, occurs in about 25% of patients with psoriasis (PsO). At present, there are no biomarkers that reliably…
Abstract Number: 0378 • ACR Convergence 2020
Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
Joseph Merola¹, Peter Taylor², Andrew Bushmakin³, Joseph Cappelleri³, Pamela Young⁴, Rebecca Germino⁵ and Gil Yosipovitch⁶, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, New York, NY, ⁶University of Miami, Miami, FL
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease with signs and symptoms across multiple domains, including cutaneous manifestations, which can impact health-related quality…
Abstract Number: 0402 • ACR Convergence 2020
Optical Coherence Tomography of the Skin Detects Scleroderma Changes in Clinically Unaffected Skin: An Opportunity for Early Detection of Systemic Sclerosis
Giuseppina Abignano¹, Duygu Temiz Karadag², Ozcan Gundogdu³, Giovanni Lettieri⁴, Maria Carmela Padula⁵, Angela A Padula⁵, Paul Emery⁶, Salvatore D'Angelo⁵ and Francesco Del Galdo⁶, ¹Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Potenza, Italy, ²Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey, Kocaeli, Turkey, ³Department of Biomedical Engineering, Kocaeli University, Kocaeli,Turkey, Kocaeli, Turkey, ⁴Radiology Department, San Carlo Hospital, Potenza, Italy, Potenza, Italy, ⁵Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, Potenza, Italy, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: The Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) study has shown that more than 80% of patients with Raynaud’s Phenomenon, specific ANA positivity and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].